Exel announces new business with Bristol-Myers Squibb and expansion of Midwest Footprint

Global biopharmaceutical company, Bristol-Myers Squibb, has chosen Exel as its third-party logistics provider handling its U.S. distribution. As part of the contract, Exel purchased the existing Bristol-Myers Squibb distribution centers in Mount Vernon, Ind., and will take over operations in the second quarter of this year.

Exel will provide logistics operations and finished goods distribution services including storage and distribution of cold and non-cold chain products, clinical trials, samples and exports. Shortly after it takes over operations in Mount Vernon, Exel will open and manage a second distribution center on its Mechanicsburg, Penn., campus for Bristol-Myers Squibb. This two-facility distribution strategy will ensure best-in-class service to Bristol-Myers Squibb and support the company in bringing its medicines to patients in need.

Under Exel's ownership and management of the Mount Vernon site, Bristol-Myers Squibb will remain a primary customer served at the facility, with the pportunity to add additional Exel customers in the future to create a shared-use pharmaceutical distribution site.

"Exel's expertise in both the life sciences sector and real estate was crucial in creating the right solution for Bristol-Myers Squibb," said Joe Puleo, Exel's senior vice president of business development for the life sciences industry. "We are proud to work with such a leading biopharmaceutical company and share its commitment to delivering innovative medicines that help patients prevail over diseases."

Located near Evansville, Ind., the Mount Vernon distribution center is just 80 miles from the center of all U.S. population demand. It also offers close proximity to a number of key parcel and air infrastructure hubs including Indianapolis and Louisville, Ky.

Bristol-Myers Squibb will continue to operate its manufacturing and research and development facilities, also located in Mount Vernon, and remains committed to the local community.

Suggested Articles

BMS’s Opdivo has plenty of competition in its current bladder cancer indication—so it’s hoping to strike out on its own in a new area of the disease.

The Japanese approval, under the brand name Jyseleca, came a month after an FDA complete response letter that asked Gilead for more data.

The Trump Administration has opened the doors for Florida and other states to import prescription drugs from Canada—despite industry objections.